Medvest Capital
Medvest Capital is a venture capital firm based in West Palm Beach, Florida, founded in 2013. The firm is dedicated to supporting early-stage companies in the life sciences, healthcare, and medical device sectors. Medvest Capital operates on three core principles: improving patient outcomes, decreasing delivery costs, and minimizing provider risk. In addition to providing financial investment, the firm collaborates closely with the management teams of its portfolio companies to validate market feasibility, accelerate product development, and implement sustainable business processes. Medvest typically invests between $1 million and $3 million in its target companies.
6 past transactions
Osteal Therapeutics
Series C in 2023
Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company’s therapeutics are designed to significantly reduce the mortality, morbidity, and healthcare costs associated with these infections. Osteal Therapeutics offers solutions for orthopedic infections and infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for patients suffering from musculoskeletal diseases, ultimately improving patient outcomes and the overall management of these conditions.
BrightSpec
Series C in 2022
BrightSpec specializes in innovative analytical chemistry services, utilizing its proprietary Fourier transform molecular rotational resonance (FT-MRR) technology. Based in Charlottesville, Virginia, the company delivers immediate results to clients, addressing high-value, time-sensitive challenges not well served by other spectroscopy techniques. Its platform offers configurations for manufacturing process control, quality control, environmental monitoring, and formulation research.
Osteal Therapeutics
Series B in 2022
Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company’s therapeutics are designed to significantly reduce the mortality, morbidity, and healthcare costs associated with these infections. Osteal Therapeutics offers solutions for orthopedic infections and infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for patients suffering from musculoskeletal diseases, ultimately improving patient outcomes and the overall management of these conditions.
Providence Medical Technology
Series E in 2016
Providence Medical Technology is a medical device company specializing in innovative solutions for cervical spinal conditions. It offers the DTRAX platform, including instruments and implants designed to treat cervical degenerative disc disease via indirect decompression and fusion.
Providence Medical Technology
Series D in 2015
Providence Medical Technology is a medical device company specializing in innovative solutions for cervical spinal conditions. It offers the DTRAX platform, including instruments and implants designed to treat cervical degenerative disc disease via indirect decompression and fusion.
Providence Medical Technology
Series C in 2014
Providence Medical Technology is a medical device company specializing in innovative solutions for cervical spinal conditions. It offers the DTRAX platform, including instruments and implants designed to treat cervical degenerative disc disease via indirect decompression and fusion.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.